China’s Shanghai Green Valley Pharmaceuticals has clearance to begin a late stage clinical trial to support a US filing of its potential Alzheimer’s drug.
China’s drugs regulator has conditionally approved Shanghai Green Valley Pharmaceuticals’ Oligomannate to improve cognitive function in mild to moderate Alzheimer’s disease, the first novel
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh